Show me the money: The cost of epidemic control

Edinah Mudimu holds the position of senior lecturer at the University of South Africa within the Department of Decision Sciences. Her area of expertise lies in utilizing simulation modelling to tackle public health questions, with a specific focus on evaluating the effectiveness of prevention and treatment programs pertaining to HIV and other infectious diseases. Her research interests also encompass conducting economic evaluations and cost-effectiveness analyses to further enhance the understanding of these interventions and their impact.

 

Dr. Andrew Hill, MD, is a senior visiting Research Fellow in the Pharmacology Department at Liverpool University.

Dr. Neilan is Assistant Professor of Pediatrics and Assistant Professor of Medicine at Harvard Medical School, as well as an Assistant in Pediatrics and an Assistant in Medicine in the Division of Infectious Diseases, both at Massachusetts General Hospital.

Dr. Uetela completed a medical degree at Eduardo Mondlane University in 2009, a master's in health sciences at the Fiocruz in 2015, and a PhD in implementation science at the University of Washington in 2023. Her research interests include health system strengthening and HIV service delivery. She has led the HIV cluster of the Mozambique national health observatory and conducted a process, impact, and economic evaluation of the nationwide implementation of eight differentiated service delivery models for HIV treatment being implemented in Mozambique since 2018. 

Emily Hyle is a Clinician-Investigator in the Division of Infectious Diseases at the Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. As a member of the Cost-effectiveness of Preventing AIDS Complications (CEPAC) research team, her research focuses on using simulation modelling & cost-effectiveness analysis to investigate clinical and public health interventions for people with HIV. Funded by the National Institutes of Health (NIH), Emily has led & contributed to model-based analyses that include studies on HIV and non-communicable comorbidities, HIV drug resistance, laboratory monitoring, point-of-care testing and loss to follow up. Her research is cited in the US Department for Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, as well as the World Health Organization (WHO) Consolidated guidelines on the use of antiretroviral drugs for treating & preventing HIV infection.